Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Tempium Discontinued Following Abnormal Liver Tests In Phase III

Executive Summary

Elevated bilirubin and liver transaminase levels in a Phase III trial led to discontinuation of development of Roche's Tempium (lazabemide). The company announced the halt of the Alzheimer's therapy program on Sept. 14.

You may also be interested in...



SB Relinquishes Frovatriptan Royalties As Final Step In Antitrust Review

SmithKline Beecham will receive up to $25 mil. in payments from Vernalis in exchange for surrendering its 7% royalty on the pending antimigraine agent Miguard (frovatriptan).

SB Relinquishes Frovatriptan Royalties As Final Step In Antitrust Review

SmithKline Beecham will receive up to $25 mil. in payments from Vernalis in exchange for surrendering its 7% royalty on the pending antimigraine agent Miguard (frovatriptan).

Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do

Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.

Related Content

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel